BRAVE-AA-PEDS

Paediatric clinical trial of baricitinib in adolescents with severe alopecia areata, in which 42% of those treated with 4 mg achieved at least 80% scalp hair coverage (SALT ≤20) at week 36. It formed the basis for the CHMP's positive opinion on extending the drug's use to adolescents aged 12 to under 18.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.